SIMIONI, Carolina
 Distribuzione geografica
Continente #
NA - Nord America 4.173
AS - Asia 2.448
EU - Europa 1.960
SA - Sud America 410
AF - Africa 52
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 3
Totale 9.054
Nazione #
US - Stati Uniti d'America 4.053
SG - Singapore 945
CN - Cina 557
PL - Polonia 519
IT - Italia 506
BR - Brasile 327
VN - Vietnam 299
DE - Germania 232
HK - Hong Kong 185
GB - Regno Unito 129
UA - Ucraina 126
TR - Turchia 95
FI - Finlandia 94
FR - Francia 90
IN - India 76
JP - Giappone 71
CA - Canada 64
RU - Federazione Russa 64
SE - Svezia 60
ID - Indonesia 57
MX - Messico 48
AR - Argentina 33
BD - Bangladesh 33
NL - Olanda 32
PK - Pakistan 24
IQ - Iraq 23
ZA - Sudafrica 21
ES - Italia 19
BE - Belgio 18
CO - Colombia 15
AT - Austria 12
EC - Ecuador 10
VE - Venezuela 9
AL - Albania 8
IE - Irlanda 8
LT - Lituania 8
UZ - Uzbekistan 8
AU - Australia 7
HU - Ungheria 7
KE - Kenya 7
MY - Malesia 7
PH - Filippine 7
CZ - Repubblica Ceca 6
JO - Giordania 6
NP - Nepal 6
PY - Paraguay 6
SA - Arabia Saudita 6
AE - Emirati Arabi Uniti 5
CH - Svizzera 5
CL - Cile 5
DZ - Algeria 5
IR - Iran 5
MA - Marocco 5
EG - Egitto 4
TW - Taiwan 4
AZ - Azerbaigian 3
BH - Bahrain 3
BO - Bolivia 3
CG - Congo 3
HR - Croazia 3
IL - Israele 3
KR - Corea 3
LB - Libano 3
SN - Senegal 3
TN - Tunisia 3
CY - Cipro 2
DO - Repubblica Dominicana 2
EU - Europa 2
KG - Kirghizistan 2
KW - Kuwait 2
OM - Oman 2
RO - Romania 2
RS - Serbia 2
SI - Slovenia 2
SV - El Salvador 2
AM - Armenia 1
BG - Bulgaria 1
CR - Costa Rica 1
GE - Georgia 1
GR - Grecia 1
GY - Guiana 1
HN - Honduras 1
IM - Isola di Man 1
IS - Islanda 1
JM - Giamaica 1
KH - Cambogia 1
KZ - Kazakistan 1
LK - Sri Lanka 1
LU - Lussemburgo 1
LV - Lettonia 1
MD - Moldavia 1
PS - Palestinian Territory 1
PT - Portogallo 1
ST - Sao Tome e Principe 1
TO - Tonga 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 9.054
Città #
Singapore 598
Warsaw 517
Ashburn 507
Fairfield 383
San Jose 312
Woodbridge 280
Houston 223
Beijing 180
Hong Kong 175
Ferrara 174
Chandler 172
Santa Clara 172
Seattle 157
Ann Arbor 156
Cambridge 144
Wilmington 139
Jacksonville 128
Dallas 92
Ho Chi Minh City 88
Milan 82
Los Angeles 81
Council Bluffs 78
Hanoi 72
Tokyo 67
Munich 66
Izmir 55
New York 54
Princeton 49
Helsinki 48
Jakarta 47
Nanjing 47
Lauterbourg 45
Shanghai 42
São Paulo 32
San Diego 31
Bologna 29
Frankfurt am Main 27
Boardman 25
Dearborn 24
Dong Ket 24
Mexico City 23
Buffalo 20
Montreal 20
Atlanta 19
Turku 19
Brussels 18
Nanchang 18
Orem 18
Shenyang 18
Hefei 17
Falkenstein 16
London 16
Chennai 15
Phoenix 15
Denver 14
Rio de Janeiro 14
Bengaluru 13
Da Nang 13
Montréal 12
Poplar 12
Stockholm 12
Baghdad 11
Boston 11
Changsha 11
Haiphong 11
Rome 11
San Francisco 11
Auburn Hills 10
Guangzhou 10
Johannesburg 10
Paris 10
Amsterdam 9
Brasília 9
Brooklyn 9
Chicago 9
Columbus 9
Kunming 9
Moscow 9
Nuremberg 9
Toronto 9
Curitiba 8
Hebei 8
Hải Dương 8
Jinan 8
Lahore 8
Manchester 8
Ankara 7
Belo Horizonte 7
Bremen 7
Bắc Ninh 7
Dublin 7
Mumbai 7
Porto Alegre 7
Redwood City 7
Tashkent 7
Tianjin 7
Zhengzhou 7
Addison 6
Budapest 6
Campinas 6
Totale 6.294
Nome #
Targeting mTOR in Acute Lymphoblastic Leukemia 292
PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines 285
Healthy CD4+ T lymphocytes are not affected by targeted therapies against the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia 272
Cell cycle block by p53 acrivation reduces SARS-COV-2 release in infected alveolar basal epithelial A549-hACE2 cells 265
Cell cycle block by p53 activation reduces SARS-CoV-2 release in infected alveolar basal epithelial A549-hACE2 cells 264
miR-199a-3p Modulates MTOR and PAK4 Pathways and Inhibits Tumor Growth in a Hepatocellular Carcinoma Transgenic Mouse Model 260
PHARMACOLOGICAL CHARACTERIZATION OF THE SIGNAL TRANSDUCTION PATHWAYS MODULATED BY A3 RECEPTORS IN CANCER CELLS: POSSIBLE TARGETS FOR THERAPEUTIC INTERVENTION. 257
The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells 253
Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia 253
Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia 248
miRNAs as Influencers of Cell-Cell Communication in Tumor Microenvironment 242
Oxidative stress: role of physical exercise and antioxidant nutraceuticals in adulthood and aging 238
Targeting the phosphatidylinositol 3-kinase/Akt/mechanistic target of rapamycin signaling pathway in B-lineage acute lymphoblastic leukemia: An update 235
Physical training interventions for children and teenagers affected by acute lymphoblastic leukemia and related treatment impairments 228
Adenosine modulates vascular endothelial growth factor expression via hypoxiainducible factor-1 in human glioblastoma cells. 226
Adenosine receptors and cancer 220
M3 muscarinic receptors in peripheral lung parenchima of patients with chronic obstructive pulmonary disease. 208
Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential 198
Pharmacological characterization of adenosine receptors in bovine chondrocytes. 188
Binding thermodynamics at the human cannabinoid CB1 and CB2 receptors 188
Caffeine inhibits adenosine-induced accumulation of hypoxia-inducible factor-1α, vascular endothelial growth factor, and interleukin-8 expression in hypoxic human colon cancer cells 185
SARS-CoV-2 nucleocapsid-protein and ultrastructural modifications in small bowel of a four week negative COVID-19 patient 178
L'ipossia inibisce l'apoptosi indotta da paclitaxel mediante fosforilazione di BAD dipendente dall'adenosina nelle cellule di glioblastoma. 176
Optical tissue clearing associated with 3D imaging: application in preclinical and clinical studies 170
Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia 166
Cytotoxic drugs regulate VEGF and IL-8 expression in human melanoma cells by A2A and A3 adenosine receptors. 166
A3 ADENOSINE RECEPTORS MODULATE HYPOXIA-INDUCIBLE FACTOR-1ALPHA EXPRESSION IN HUMAN CANCER CELLS 165
Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent AKT reactivation. 164
New biomarkers and therapeutic strategies in acute lymphoblastic leukemias: recent advances 161
PI3K/Akt/mTOR Pathway in Acute Lymphoblastic Leukemia Targeted Therapies 153
Legislation to limit the environmental plastic and microplastic pollution and their influence on human exposure 152
Binding thermodynamics at the human A2B adenosine receptor. 149
Relevance of VEGF and CD147 in different SARS-CoV-2 positive digestive tracts characterized by thrombotic damage 146
The Complexity of the Tumor Microenvironment and Its Role in Acute Lymphoblastic Leukemia: Implications for Therapies 143
Micrornas patterns as potential tools for diagnostic and prognostic follow‐up in cancer survivorship 140
Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation. 139
The role of extracellular vesicles as shuttles of RNA and their clinical significance as biomarkers in hepatocellular carcinoma 132
A2B AND A3 ADENOSINE RECEPTORS MODULATE VASCULAR ENDOTHELIAL GROWTH FACTOR AND INTERLEUKIN-8 EXPRESSION IN HUMAN MELANOMA CELLS TREATED WITH ETOPOSIDE AND DOXORUBICIN. 127
Microalgae as a Nutraceutical Tool to Antagonize the Impairment of Redox Status Induced by SNPs: Implications on Insulin Resistance 126
Effects of SARS-COV-2 on molecules involved in vascularization and autophagy in placenta tissues 122
VEGF and IL-8 regulation by cytotoxic drugs in human melanoma cells: molecular mechanism modulated by A2B and A3 adenosine receptors 118
Two neuroendocrine G protein-coupled receptor molecules, somatostatin and melatonin: Physiology of signal transduction and therapeutic perspectives 115
null 112
Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia. 108
The novel Akt inhibitor MK-2206, is cytotoxic in T-cell acute lymphoblastic leukemia: Therapeutic implications 106
The mTOR inhibitor, RAD001, displays higher cytotoxicity in leukemias with hyperactivated PI3K/AKT/mTOR pathway 100
null 95
The AKT Inhibitor MK-2206 is Cytotoxic in Hepatocarcinoma Cells Displaying Hyperphosphorylated AKT-1 and Synergizes with Conventional Chemotherapy 92
Therapeutic potential of the novel mTOR inhibitor Torin-2 to overcome AKT reactivation in B-precursor acute lymphoblastic leukemia (B-pre ALL). 88
null 86
null 86
null 84
Regulation of Second Messenger Systems and Intracellular Pathways. 72
Increase of VEGF and Fibronectin expression and ultrastructural alterations of intercellular junctions in a swab negative patient after SARS-COV-2 infection 62
Cytokines, Signaling and Epigenetic Mechanisms: Shaping the Acute Lymphoblastic Leukemia Microenvironment 10
Totale 9.214
Categoria #
all - tutte 38.757
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.425
Totale 40.182


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021306 0 0 0 0 0 0 0 0 0 169 69 68
2021/2022434 20 35 21 4 36 36 13 35 15 47 55 117
2022/2023467 55 36 26 42 60 49 42 31 45 30 37 14
2023/2024299 28 35 22 6 15 29 19 22 5 10 15 93
2024/20251.414 39 47 115 74 180 125 93 71 223 135 162 150
2025/20263.551 428 126 306 449 520 303 468 202 359 390 0 0
Totale 9.214